Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences
Current Oncology · 2025
DOI: 10.3390/curroncol32040240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Valentyn Litvin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, University of Montréal, Montréal, QC H3T 1J4, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chaire pharmaceutique Sanofi sur l'usage optimal des médicaments de l'Université de Montréal, Réseau québécois de recherche sur les médicaments (RQRM) / Fonds de recherche du Québec (FRQS), Chaire pharmaceutique Sanofi sur l’usage optimal des médicaments de l’Université de Montréal.
Abstract (Originalsprache)
There has been a proliferation of novel treatments for the management of advanced prostate cancer (PCa), including androgen receptor pathway inhibitors (ARPI). Although there are health economic analyses of novel PCa treatments, such as ARPIs for specific health states, there is a lack of sequential analyses. Our paper aims to fill this gap. We developed a Monte Carlo Markov model to simulate the management of advanced PCa to end-of-life. We modeled patients who begin in metastatic and nonmetastatic castration-sensitive PCa (mCSPC and nmCSPC), with risk stratification for mCSPC, progressing to metastatic castration-resistant PCa (mCRPC). Using current guidelines and recent literature, we simulated admissible treatment sequences over these states along a 15-year horizon. We report the best treatment sequences in terms of efficacy and cost-effectiveness. We find that the most cost-effective use of ARPIs is early in advanced PCa for a cost-effectiveness threshold (CET) of CAD 100K per QALY. For a CET of CAD 50K per QALY, early ARPI use is most cost-effective in mCSPC-starting patients but not nmCSPC-starting. We conclude that the most cost-effective way to use ARPIs is when patients first enter advanced PCa. The most cost-effective ARPI at current Canadian prices is abiraterone, mostly due to abiraterone’s lower price level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, University of Montréal, Montréal, QC H3T 1J4, Canada.
- Division of Urology, McGill University, Montréal, QC H4A 3J1, Canada.
ORCID-Profile: Valentyn Litvin
Förderung
- Chaire pharmaceutique Sanofi sur l'usage optimal des médicaments de l'Université de Montréal
- Réseau québécois de recherche sur les médicaments (RQRM) / Fonds de recherche du Québec (FRQS)
- Chaire pharmaceutique Sanofi sur l’usage optimal des médicaments de l’Université de Montréal
- Réseau québécois de recherche sur les médicaments (RQRM)/Fonds de recherche du Québec (FRQS)
Zitieren
APA
Litvin, V., Aprikian, A. G., & Dragomir, A. (2025). Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences. Current Oncology. https://doi.org/10.3390/curroncol32040240
Vancouver
Litvin V, Aprikian AG, Dragomir A. Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences. Current Oncology. 2025. doi:10.3390/curroncol32040240
BibTeX
@article{Litvin2025,
author = {Litvin, Valentyn and Aprikian, Armen G and Dragomir, Alice},
title = {Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32040240}
}
EUVIMED